Better Therapeutics files for FDA approval of new type of digital therapy for diabetes

Sep. 22, 2022 9:17 AM ETBetter Therapeutics, Inc. (BTTX)By: Ravikash, SA News Editor

Headquarters of US Food and Drug Administration (FDA)


  • Better Therapeutics (NASDAQ:BTTX) said it filed a de novo classification request to the U.S. Food and Drug Administration (FDA) seeking approval of digital device BT-001 to use cognitive behavioral therapy (CBT) to treat type 2 diabetes (T2D) in patients 18 years and older.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.